TY - JOUR
TI - Coronavirus in Hematologic Malignancies: Targeting Molecules Beyond the Angiotensin-Converting Enzyme 2 (ACE2) Wall in COVID-19
AU - Tsiambas, E.
AU - Papanikolaou, V.
AU - Chrysovergis, A.
AU - Mastronikolis, N.
AU - Ragos, V.
AU - Kavantzas, N.
AU - Lazaris, A.C.
AU - Kyrodimos, E.
JO - Pathology and Oncology Research
PY - 2020
VL - 26
TODO - 4
SP - 2823-2825
PB - Springer-Verlag
SN - 1219-4956
TODO - 10.1007/s12253-020-00810-6
TODO - angiotensin converting enzyme 2;  furin;  guanine nucleotide binding protein;  hypoxia inducible factor 1alpha;  vasculotropin;  vasculotropin receptor;  angiotensin converting enzyme 2;  biological marker;  dipeptidyl carboxypeptidase, Coronavirinae;  coronavirus disease 2019;  hACE2 gene;  hematologic malignancy;  human;  hypoxia;  Letter;  Middle East respiratory syndrome coronavirus;  mortality rate;  nonhuman;  oxygen supply;  phylogeny;  RNA sequence;  SARS coronavirus;  Severe acute respiratory syndrome coronavirus 2;  single nucleotide polymorphism;  virus cell interaction;  virus entry;  virus genome;  virus pneumonia;  Betacoronavirus;  complication;  Coronavirus infection;  genetics;  hematologic disease;  immunocompromised patient;  pandemic;  pathogenicity;  pathophysiology;  physiology;  virology;  virus pneumonia, Betacoronavirus;  Biomarkers;  Coronavirus Infections;  Hematologic Neoplasms;  Humans;  Immunocompromised Host;  Pandemics;  Peptidyl-Dipeptidase A;  Pneumonia, Viral;  Polymorphism, Single Nucleotide
TODO - null
ER -